⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
about
PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literaturePositron Emission Tomography (PET) in OncologyEffects of chelator modifications on (68)Ga-labeled [Tyr (3)]octreotide conjugates.68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotateBiochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine TumorsNew Tris(hydroxypyridinone) Bifunctional Chelators Containing Isothiocyanate Groups Provide a Versatile Platform for Rapid One-Step Labeling and PET Imaging with (68)Ga(3.).Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in IndiaProspective of ⁶⁸Ga-radiopharmaceutical development.PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India.Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of αvβ3 Integrin Expression with Gallium-68.Review: Receptor Targeted Nuclear Imaging of Breast Cancer.Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis.Neuroendocrine tumours: the role of imaging for diagnosis and therapy.Use of radioactive substances in diagnosis and treatment of neuroendocrine tumorsEvolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.Imaging in neuroendocrine tumors: an update for the clinician.Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.Imaging features of malignant abdominal neuroendocrine tumors with rare presentation.Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours.Prospective of 68Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation.Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT.Impact of Ga-DOTA-Peptide PET/CT on the Management of Gastrointestinal Neuroendocrine Tumour (GI-NET): Malaysian National Referral Centre Experience
P2860
Q26992201-2AE5C654-CFB9-484B-9400-38F836AB8DE5Q34774840-5B4E7EAC-6171-46FD-A658-87C822583069Q35087810-8297DD29-2A35-4136-AAC4-30AC71308BC8Q35894770-BC1BC597-68F1-4077-8C5E-E710D37C5443Q36143456-819A1F34-C878-48CE-90F5-6F3157F19E3EQ36330126-2E788274-17FC-4FE6-A0EF-360976A89753Q36595679-DB3D94C4-CE2D-4806-98E4-9A277E64643DQ36936960-A7E10511-7AB3-4CB5-B704-E4D74EDE91FCQ37435222-0BA4CB8D-8600-40CA-B872-442F4937D779Q37592451-5213DE24-A56A-464B-B278-95666027CDB3Q37648915-E95A6FEE-9059-4863-AB46-7BF2CCEBA1E1Q37690662-91AFF86F-5858-457B-963D-E3CA5FD94ECFQ37731335-E0F4917D-52B2-4A8F-8EB0-C2BE80D91C81Q38123057-AA64684A-946A-494F-AA21-15F1BB9318E3Q38169928-4D9C3B56-D0CD-4F6B-993C-A758954CCE44Q38469898-62988FD3-8231-4E85-B2A9-CB6292B46E1DQ38544844-BDFA664B-C0DC-4245-BD80-4F676157F6A3Q38563625-64AB7B4F-B5E3-4CFB-A048-B8094083ACDAQ40051095-0595B95D-5201-4966-9E5F-CBD83CC734BBQ42345704-E9390125-4C2A-4312-A96B-7A037A1D91EEQ49303197-4221DC6F-F4B3-4D19-A69C-0B068EB77213Q49968219-6C4EFD24-C650-46FD-B6BF-F2083D75AC8DQ51789503-3BE98186-E9C4-4A6D-A399-2415BA49CC34Q54257268-28776805-4DD9-44B0-B6A2-CE4A9B003641Q55286801-03183DC6-BDF1-4BAC-A9BC-BBB46C6AC302Q56561029-58CF83FF-1B51-4EC5-A18F-0F20D25126D1
P2860
⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
@en
⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
@nl
type
label
⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
@en
⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
@nl
prefLabel
⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
@en
⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
@nl
P2860
P1476
⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
@en
P2093
Paola Tomassetti
Stefano Fanti
P2860
P2888
P304
P356
10.1007/S00259-011-1989-4
P478
39 Suppl 1
P577
2012-02-01T00:00:00Z